Bunge Global SA

BG
Investment Thesis · Updated May 28, 2026 · Coverage 2026-Q2
Free primer — Business model and recent catalysts as thesis context (steps 1 & 3 of 21). The full investment thesis, moat analysis, scenario analysis, and institutional/insider activity are available via the full research tier.

Business Model


source: coverage-next-full ticker: BG step: 01 title: Business Model (Overview) date: 2026-05-28

Step 01 — Business Model

Key Findings

  • What BG does (one line): Bunge Global is the world's largest oilseed processor by capacity and, post-Viterra, one of the four dominant global grain merchants, monetizing the spread between farmer-origination prices and downstream food/feed/fuel demand [S1][S2].
  • Operating model is dual-layer: (1) an asset-heavy industrial business — crush plants, port elevators, refineries — earning margin on physical throughput; (2) a commercial trading book — origination basis, freight, futures, and biofuel arbitrage — that can swing quarterly EBIT by hundreds of millions [S3].
  • Four reporting segments post-Viterra (effective Q3 2025): Soybean Processing & Refining, Softseed Processing & Refining, Tropical Oils & Specialty Ingredients, Grain Merchandising & Milling [S4]. Q1 2026 segment Adj EBIT contribution was 57%/30%/7%/7% respectively — heavily soybean-led.
  • Value-chain position: BG sits in layers 1-4 (origination, logistics, processing, refining); it does not operate downstream branded consumer foods (unlike ADM Nutrition or Cargill's specialty ingredient lines), nor upstream farm ownership [S5].
  • Net read: MIXED-POSITIVE for thesis. Scale is now unmatched globally in oilseed processing; the strategic gap vs ADM is the lighter downstream specialty footprint. Bull case: synergies + biofuel pull-through. Bear case: commodity-cycle exposure with diluted equity base.

Implications for Thesis and Valuation

  • BG is fundamentally a spread business, not a fee/recurring-revenue model. Valuation framework must accept cyclical earnings.
  • The post-Viterra entity is more grain-merchandising-tilted than the standalone Bunge of 2019-2024 — closer in shape to ADM than to a pure crushing comp.
  • The biggest valuation lever is the next-3-years average mid-cycle crush margin assumption (highly sensitive — modeled in Step 14 of /complete-coverage).
  • BG's earnings are NOT linear / extrapolable from any single year; CY2023 was a high-margin year ($14.87 GAAP EPS), CY2024 was trough ($7.99), CY2025 reported ($4.91 GAAP / $7.57 adj) reflects integration drag.

Objective

Describe what Bunge does in plain language, map its value-chain position, identify revenue streams and economics, document the segment structure post-Viterra, and frame the operating-vs-trading split that drives quarterly variance.

Narrative Analysis

What BG actually does

In any given month, Bunge:

  1. Buys raw oilseeds (mostly soybeans, canola, sunflower seed) and grains (wheat, corn) from farmers in Brazil, Argentina, US Midwest, Canada, EU, Black Sea, and Australia — increasingly so via Viterra's elevator network.
  2. Moves them via owned-and-leased port terminals, river barges, rail, and trucks — the logistical optimization across origin/destination pairs being one of the trading book's main P&L levers.
  3. Crushes oilseeds into vegetable oil + protein meal at ~75-80 plants worldwide.
  4. Refines crude vegetable oil into branded/private-label cooking oils, bottled oils, margarine bases, biofuel feedstock.
  5. Mills wheat and corn into flour and dry-mill products.
  6. Sells to: food manufacturers (Nestle, Unilever, P&G's food brands, Procter & Gamble, Cargill itself for further processing), animal feed mills, foodservice distributors, biofuel producers (Chevron under the JV, plus arm's-length sales to Phillips 66, Marathon, Valero), and end-customers via private-label oils [S1].
Layered value-chain map
Layer 1: Origination — farmer-facing, basis-pricing
   ↓ (Bunge legacy: light; Viterra: heavy)
Layer 2: Logistics — port elevators, river/rail/truck, storage
   ↓ (Bunge + Viterra combined)
Layer 3: Processing — crush plants (oilseeds), mills (wheat/corn)
   ↓ (Bunge core competency, largest globally post-Viterra)
Layer 4: Refining & Distribution — refined oils, lecithin, specialty ingredients
   ↓ (Bunge: present; ADM: deeper)
Layer 5: Branded Consumer / Specialty — NOT operated by BG

[S1][S5]

Revenue streams

BG's segment structure post-Viterra (effective Q3 2025) [S4]:

Segment What it sells Q1 2026 Revenue Q1 2026 Adj EBIT EBIT Margin
Soybean Processing & Refining Soybean oil + soy meal; refined soybean oil $9,552M $377M 3.9%
Softseed Processing & Refining Canola, sunflower, rapeseed → oil + meal; refined oils $3,904M $195M 5.0%
Tropical Oils & Specialty Ingredients Palm, coconut, specialty oils, lecithin, soy protein concentrates $1,228M $45M 3.7%
Grain Merchandising & Milling Origination, trading, port elevators, wheat/corn milling $7,177M $44M 0.6%
Total $21,861M $661M (Adj segment EBIT) 3.0%

[S4]

Operating-vs-trading split

A single Q1 reading suggests that BG's processing segments earn ~3-5% segment Adj EBIT margins from physical throughput, while the Grain Merchandising & Milling segment runs at ~0-1% margin most of the time because it's effectively a flow business: high revenue (port + elevator + trading throughput), low fixed margin per ton, with EBIT swinging when basis spreads or freight arbs open up. This is a fundamental difference from pure-play food companies — BG's trading book is a real risk and earnings line, not back-office hedging [S6].

The Chevron JV (Bunge Chevron Ag Renewables)

50/50 joint venture with Chevron. Bunge contributed soybean processing facilities in Destrehan, LA and Cairo, IL; Chevron contributed ~$600M cash. Capacity goal: expand from 7,000 tons/day (end 2024) to ~14,000 tons/day by end 2026. Sells low-CI soybean oil to Chevron's renewable diesel refineries. This is equity-method consolidation (not part of BG's reported revenue), but it is a strategic optionality on US biofuel mandates [S7]. Secondary track applies here: this asset is best valued via standard DCF / capacity multiples, not commodity-cycle logic.

What BG is NOT
  • Not a branded consumer foods company (no Mazola/Wesson equivalent at scale within BG; some specialty oils are branded but small)
  • Not an agronomy / seed company (no equivalent to Corteva or Bayer Crop Science)
  • Not a fertilizer or crop protection player
  • Not vertically integrated upstream into farm operations

This shapes the moat assessment: BG's moat — if any — is in scale, geographic optionality, and trading book skill, not in IP or brand. (Tested in Step 10.)

Evidence and Sources

  • Segment structure and Q1 2026 segment Adj EBIT: company Q1 2026 press release [S4]
  • Value-chain position vs ADM: peer comparison and industry analysis [S5]
  • Chevron JV mechanics and capacity: 2023 biodieselmagazine + biofuels-news coverage [S7]
  • General BG description and post-Viterra commentary [S1][S2][S3]

Assumption Register Updates

ID Step Assumption Type Value Unit Basis Sensitivity Source
A05 01 BG is a spread/cycle business; valuation must NOT linear-extrapolate any single year Judgment Sector track + segment economics High A05
A06 01 Combined entity segment mix: Soy P&R ~45% revenue / 57% Adj EBIT; Softseed ~18%/30%; Tropical ~6%/7%; Grain Merch ~33%/7% Estimate mix Q1 2026 segment data Medium (one-quarter sample) A06
A07 01 Bunge Chevron JV equity-method; not in consolidated revenue but real strategic asset Fact JV documentation [S7] Low (yet) A07

Tables and Calculations

Segment Mix — Q1 2026 (one-quarter sample)
Segment Revenue Mix Adj EBIT Mix Margin (Adj EBIT / Rev)
Soybean P&R 43.7% 57.0% 3.9%
Softseed P&R 17.9% 29.5% 5.0%
Tropical Oils & Specialty Ingr 5.6% 6.8% 3.7%
Grain Merchandising & Milling 32.8% 6.7% 0.6%
Total 100% 100% 3.0%
Historic Segment Structure (pre-Q3 2025)

Pre-realignment, Bunge reported as: Agribusiness, Refined & Specialty Oils, Milling, Sugar & Bioenergy. The realignment in Q3 2025 was driven by the Viterra integration and management's combined-company operating view. Direct comparability for full-year segment series will require restating prior periods — pending in /complete-coverage Step 13 work.

Open Questions and Data Gaps

  • Sugar & Bioenergy segment treatment under new 4-segment structure (likely embedded into Grain Merchandising or treated as held-for-sale separately) — to confirm from 10-K segment note
  • Customer concentration explicit disclosure
  • Geographic mix split by segment (especially South America vs North America)
  • Full-year FY2025 segment data not transcribed (only summary press release fragments)

Next-Step Dependencies

  • Step 02 will use segment structure here for industry/market positioning
  • Step 03 will need segment-level margin data for margin tree
  • Step 10 will test moat hypothesis using value-chain map

Source Index

Source Tag Document or URL Section / Page / Slide Date Notes
[S1] Bunge 10-K FY2025 summary BG_financials/sec_filings/10K_FY2025_summary.md 2026-05-28 Business description
[S2] StockAnalysis.com BG https://stockanalysis.com/stocks/bg/ 2026-05-28 Segment / ownership data
[S3] Bunge Q4 2025 + Q1 2026 press releases BG_financials/presentations/investor_presentation_2026.md 2026-05-28 Segment commentary
[S4] Bunge Q1 2026 press release SEC 8-K 000162828026028079 2026-04-29 4-segment Adj EBIT split
[S5] Competitive landscape BG_financials/industry/competitive_landscape.md 2026-05-28 Value-chain peer mapping
[S6] Market overview BG_financials/industry/market_overview.md 2026-05-28 Trading vs processing dynamics
[S7] Bunge Chevron JV announcement (2022); biofuelsmagazine 2024 update https://biodieselmagazine.com/articles/2517732/chevron-bunge-partner-on-renewable-fuel-feedstocks 2026-05-28 JV mechanics

Segment Revenue MixQ1 2026

  • Soybean Processing & Refining43.7% of rev
  • Grain Merchandising & Milling32.8% of rev
  • Softseed Processing & Refining17.9% of rev

Top Competitors

  • ADM
  • Cargill
  • Wilmar

Recent Catalysts


source: coverage-next-full ticker: BG step: 12 title: Bull vs Bear (Catalysts) date: 2026-05-28

Step 12 — Bull / Bear Debate (Catalysts)

No transcripts used. Following the skill's spec for the non-transcript path, the bull/bear analyst debate is inferred from consensus notes, press releases, recent news, the FY26 guidance trajectory, and the segment-level Q1 2026 print rather than full earnings-call discussion.

Key Findings

  • The Street is consensus bullish — 9 reporting analysts with 5 Strong Buy / 3 Buy / 1 Hold / 0 Sell; average price target $142 (15% upside) [S1].
  • The bull case rests on three legs: (1) Viterra synergy realization on the announced cadence, (2) crush margin recovery as RVO biofuel policy clarifies, (3) deleveraging path restoring earnings quality.
  • The bear case rests on three legs: (1) cycle risk — soybean / vegetable oil prices remain depressed if RVO disappoints, (2) integration drag persists longer than guided, (3) overlevered balance sheet constrains growth + dividend / buyback ability.
  • The valuation level (~13x forward EPS) is the swing factor — it's below historical avg ~15x but above peer ADM (~10x), reflecting Viterra-execution optimism. If FY26 prints ~$9.50 Adj EPS and FY27 prints $11+, the multiple expands further; if FY26 disappoints, it compresses sharply.
  • Q1 2026 print itself was the clearest catalyst — +89% beat vs consensus + guidance raise from $7.50-8.00 to $9.00-9.50 drove the stock from ~$95 (early April) to $124 (late May).
  • Net read: TILT BULLISH NEAR-TERM, BALANCED MEDIUM-TERM. Q1 print + guidance raise are real positives; the remaining 2026 quarters need to confirm the trajectory.

Implications for Thesis and Valuation

  • The bull case is in the price at $124 with consensus FY26 at $9.62 and FY27 at $11.26 (~10-11x forward — already below historical multiple)
  • For the stock to materially appreciate from here ($150+ target), FY27 needs to exceed $11.50 + multiple stays at 12-13x = $138-150
  • For the stock to materially decline from here ($95 area), one of: RVO disappoints + crush margin fades, integration cost overrun, leverage credit-rating action

Objective

Frame the bull and bear theses with quantified upside/downside scenarios, identify near-term catalysts that can move the stock, and document thesis-invalidators.

Narrative Analysis

The Bull Thesis (synthesizing the optimistic case from Q1 2026 print + Street consensus + management messaging)

Core argument: BG is at an inflection point. The Viterra integration is delivering ahead of schedule ($70M synergies realized 2025, $190M targeted 2026, $220M run-rate target). Crush margins are recovering from cycle trough (+56% YoY in soybean processing Q1 2026). The combined entity is structurally stronger than pre-merger BG. FY27 EPS power of $11-12+ is achievable at the right cycle.

Supporting points (per consensus analyst commentary):

  • 5 Strong Buy ratings; average price target $142 (+15% vs $123.83)
  • Median target $145 (+17%); high target $150 (+21%)
  • Q1 2026 beat consensus by 89% on Adj EPS
  • Mgmt raised FY26 guidance from $7.50-8.00 to $9.00-9.50 — material upward revision
  • 14 analysts covering — broad institutional interest
  • Forward P/E of 12.16 vs historical avg ~15x → multiple expansion available if earnings deliver
  • Segment-level signals: Soybean P&R +56% YoY, Softseed +138%, Tropical +96% in Q1
  • Synergy capture pace tracking ahead of management's own initial trajectory

Quantified bull case (price target $150 / +21%):

  • FY27 Adj EPS: $11.50 (above consensus $11.26)
  • Multiple: 13x forward (premium to ADM's ~10x reflecting Viterra synergy + biofuel optionality)
  • = $149-150 fair value
  • ROIC recovers to ~10% (above WACC)
  • Deleveraging on track to <3.0x by end-2027
  • Glencore lockup releases without overhang

[S1][S2][S3]

The Bear Thesis (synthesizing the bearish counterpoints)

Core argument: The Viterra deal was expensive at 8.5x pre-synergy EBITDA, dilutive (33% more shares), and the path to value-accretion requires multi-year flawless execution. The 2025-2026 commodity environment was unusually weak (soybean oil glut, China-US trade disruption, biofuel policy uncertainty), and there's no guarantee 2026-2028 will be materially better. Leverage is elevated; if anything goes wrong, BG has limited ability to deploy capital defensively.

Supporting points:

  • 1 Hold rating in current coverage; no Sell ratings (but the "Hold" matters)
  • Forward P/E of 12 is not particularly cheap on a forward earnings number that itself depends on optimistic synergy + margin assumptions
  • ROIC currently 3.5% — well below WACC; even FY27E forecast (~8.8%) is barely above
  • Net debt $14B; rating-agency action a watch-item
  • Buyback runway constrained near-term (~$300M/yr vs $1.1B in FY24)
  • ADM's 81% crushing EBIT collapse in FY25 shows what a hostile biofuel policy environment does to the segment
  • Brazilian oversupply + Argentine peso volatility create chronic margin pressure
  • Glencore monetization risk post-lockup (early 2027)
  • Climate change is a long-term structural risk for South American agriculture

Quantified bear case (price target $95 / -23%):

  • FY27 Adj EPS: $8.50 (below consensus $11.26 — synergies underdeliver, crush margins flat)
  • Multiple: 11x forward (further compression on disappointed expectations)
  • = $93-95 fair value
  • Possible rating downgrade if deleveraging slips
  • Dividend cut not likely but buybacks pause

[S1][S2]

Near-Term Catalysts (next 12 months)
Catalyst Type Direction Magnitude
Q2 2026 earnings (late July 2026) — first apples-to-apples YoY quarter Reporting Either High
Q3 2026 earnings (late October 2026) Reporting Either Medium
Q4 2026 + FY guide (Feb 2027) Reporting Either High
RVO 2026/2027 rule-setting Policy Either (likely positive) High
US-China trade dynamics evolution Policy Either Medium
Glencore lockup release start (early 2027) Capital markets Negative (overhang) Medium
Investor Day (already held March 2026) Communication n/a (passed) Low
Bunge Chevron JV plant expansion completion (end 2026) Operational Positive Low-Medium
Credit rating actions Capital markets Either Medium-High
South American crop / weather updates Operational Either Medium
Thesis Invalidators

The thesis is invalidated (i.e., long becomes sell or short) if any of these materialize:

  • FY26 Adj EPS prints below $8.00 (i.e., guidance miss + guidance cut for FY27)
  • Net Debt / EBITDA stays above 4.0x through end-2027 (deleveraging stalls)
  • Credit rating cut to BB+ / Ba1 (loss of investment grade)
  • Viterra integration impairment charge >$1B (synergy thesis broken)
  • RVO mandates cut materially in any forthcoming rule
  • Major operational accident at a flagship plant or port
What the Q1 2026 Print Told Us

Looking at the Q1 2026 results in this light: 89% beat + guidance raise — that's the strongest possible single-quarter positive signal. It suggests the bull case is currently in the driver's seat. But Q1 is a low-base quarter; the next two prints (Q2 in July 2026, Q3 in October 2026) are what confirm or deny the trajectory.

Evidence and Sources

  • Consensus + ratings: Consensus document [S1]
  • Q1 + Q4 prints: press releases [S2]
  • Synergy & guidance: management commentary [S3]
  • Peer (ADM) read-throughs: industry coverage [S4]

Assumption Register Updates

ID Step Assumption Type Value Unit Basis Sensitivity Source
A52 12 Bull case target $150 = 13x $11.50 FY27 EPS Estimate $150 $ Multiple × EPS [S1][S2] High A52
A53 12 Bear case target $95 = 11x $8.50 FY27 EPS Estimate $95 $ Multiple × EPS [S1][S2] High A53
A54 12 Probability-weighted fair value ~$130 (bull 35% + base 45% + bear 20%) Judgment $130 $ Tilt bullish near-term High A54

Tables and Calculations

Three-Scenario Fair Value Bridge
Scenario Probability FY27 Adj EPS Forward Multiple Fair Value Return vs $123.83
Bull 35% $11.50 13x $150 +21%
Base 45% $11.26 (consensus) 12x $135 +9%
Bear 20% $8.50 11x $94 -24%
Weighted Avg ~$129 +4%

Implication: at $124, the stock is roughly fairly valued on probability-weighted basis with a slight upward tilt. The Q1 print + guidance raise have already moved the price into "fair" territory; further upside requires Q2-Q3 confirmation of the trajectory.


Bull Case — 3 bullets

  • Viterra synergies ahead of pace — $70M realized in just 6 months of 2025 H2 puts the company on a track to exceed $190M FY26 target and possibly reach $250M+ run-rate by end-2027; each $100M synergy = ~$0.40 EPS uplift.
  • Crush margin recovery + biofuel pull-through — Q1 2026 Soybean P&R +56% YoY and Softseed +138% YoY signal cycle inflection; RVO clarity in 2026-2027 could expand soybean oil demand structurally and lift mid-cycle EBIT by $300-500M.
  • Combined entity at peak scale + geographic optionality — largest global oilseed processor by capacity, broadest origination footprint, and the Chevron JV embeds free option value on US renewable diesel mandates; mid-cycle ROIC recovery to 10%+ supports $150+ price target on 13x $11.50 FY27 EPS.

Bear Case — 3 bullets

  • Cycle + leverage = downside asymmetry — 4.3x current Net Debt / EBITDA combined with cycle-trough ROIC of 3.5% means any negative surprise (RVO disappointment, BRL crash, integration cost overrun) directly threatens dividend / buyback capacity and possibly investment-grade credit rating.
  • Viterra dilution requires perfect execution — 33% more shares outstanding mean FY27 EPS of $11+ requires Viterra-combined NOPAT growth of 30%+ vs FY24 standalone — a high bar dependent on synergy realization, crush margin recovery, AND clean integration with no further charges.
  • Multiple already pricing optimism — at 12x forward EPS the stock is well above ADM's ~10x; the gap reflects Viterra-execution + biofuel optionality already embedded in the price; bear case multiple compression to 11x on $8.50 FY27 EPS gets to $95, down 23%.

Open Questions and Data Gaps

  • Transcript-level management Q&A (intentionally not available; this skill's main blind spot)
  • Specific sensitivity disclosures for FY26 (typically given in investor day, March 2026)
  • Synergy-by-source breakdown (cost vs revenue)
  • 3-year FY27-FY29 medium-term outlook detail

Next-Step Dependencies

  • Step 16 will refine the variant-perception view (what the Street is NOT pricing)
  • Step 17 will examine institutional / Glencore positioning
  • Step 18 will translate this bull/base/bear set into portfolio sizing
  • Step 15 (in /complete-coverage) will build out the formal probabilistic scenarios

Source Index

Source Tag Document or URL Section / Page / Slide Date Notes
[S1] Consensus BG_financials/other/consensus.md 2026-05-28 Ratings + price targets
[S2] Bunge Q1 2026 + Q4 2025 press releases BG_financials/presentations/investor_presentation_2026.md 2026-04 / 2026-02 Beat + raise sequence
[S3] Step 07 capital allocation + Step 08 management Step_07_capital_allocation.md, Step_08_management_quality.md 2026-05-28 Synergy + management
[S4] ADM peer analysis tikr.com + finviz coverage 2026-02 Bear case parallels

Moat Analysis

Narrow

BG holds a narrow scale-based moat via crush-plant fixed-cost leverage, cornered port/elevator assets, and embedded trading process power, shared across the ABCD oligopoly.

Bull Case

Viterra synergy capture, crush margin recovery, and an underpriced Chevron biofuel JV position BG for significant earnings re-rating above current consensus.

Bear Case

Elevated post-Viterra leverage, commodity-cycle exposure, and potential Glencore stake overhang could pressure the stock if integration drags or crush margins disappoint.

Top Institutional Holders

As of 2026-03 · Total institutional: 78.58%
  1. Glencore plc15%
  2. Vanguard Group5.47% · 10.6M sh
  3. BlackRock5.5%

Full Investment Thesis

The full research tier ($2.00) adds 7 dimensions that constitute the investment thesis proper.

Moat Analysis
Durable competitive advantages, switching costs, network effects, and moat trajectory.
Investment Thesis
Variant perception, key assumptions, what has to be true, and why the market may be wrong.
Bull / Base / Bear Scenarios
Three discrete scenarios with probability weights, catalysts, and price targets.
Risk Register
Macro, competitive, execution, and regulatory risks with materiality ratings.
Management Quality
Capital allocation track record, incentive alignment, and tenure analysis.
DCF Valuation
10-year DCF with sensitivity matrix across revenue growth and margin assumptions.
Institutional & Insider Activity
13F holder concentration, insider Form 4 transactions, net selling/buying trends, and ownership-structure context.
View Investment MemoGET /api/v1/research/BG/memo$2.00 · Bearer token required
Markdown: /stocks/bg/thesis/md · ← financials · → memo